维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

15篇 您的检索式：作者名="Bakrin"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: A prospective study of 216 patients显示文摘	G. Passot N. Bakrin A.S. Roux D. Vaudoyer F.-N. Gilly O. Glehen E. Cotte	2013	European Journal of Surgical Oncology2013，，：	2
	2	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy(HIPEC)for persistent and recurrent advanced ovarian carcinoma:a multicenter,prospective study of 246patients显示文摘	Bakrin N Cotte E Golfier F	2012	Annals of Surgical Oncology2012，19，：	1
	3	Iterative procedures combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal recurrence: Postoperative and long‐term results显示文摘	Nicolas Golse Naoual Bakrin Guillaume Passot Faheez Mohamed Delphine Vaudoyer Fran?ois‐N?el Gilly Olivier Glehen Eddy Cotte	2012	J Surg Oncol2012，，2：	1
	4	Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients显示文摘	Bakrin N Bereder JM Decullier E	2013	Eur J Surg Oncol2013，39，12：	1
	5	Severe gestational hypertriglyceridemia:related complications and management显示文摘	Huissoud C Robert JM Bakrin N	2008	J Gynecol Obstet Biol Reprod2008，37，5：	1
	6	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients显示文摘	Bakrin N Cotte E Golfier F	2012	Ann Surg Oncol2012，19，13：	1
	7	Iterative procedures combining cytoreduetive surgery with hyperthermic intraperitoneal ehemotherapy for peritoneal recurrence:postoperative and long-term results显示文摘	Golse N Bakrin N Passot G	2012	J Surg Oncol2012，106，2：	1
	8	Response to: hyperthermic intraperi- toneal chemotherapy in epithelial ovarian cancer should be pro- posed in eight time point显示文摘	GLEHEN O BAKRIN N	2014	Eur J Surg Oneol2014，40，8：	1
	9	Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperther- mic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French muhicentre retrospective cohort study of 566 patients显示文摘	BAKRIN N BEREDER JM DECULLIER E	2013	Eur J Surg Oncol2013，39，12：	1
	10	Quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemo- therapy: a prospective study of 216 patients 显示文摘	PASSOT G BAKRIN N ROUX A S	2014	Eur J Surg Oncol2014，40，5：	1
	11	Iterative procedures combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal recurrence:postoperative and long-term results显示文摘	Golse N Bakrin N Passot G	2012	J Surg Oncol2012，106，2：	1
	12	Cytoreductive surgery and hy- perthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospec- tive study of 246 patients 显示文摘	Bakrin N Cotte E Golfier F et at	2012	Ann Surg Oncol2012，19，13：	1
	13	Iterative procedures combining cytore- ductive surgery with hyperthermic in- traperitoneal chemotherapy for peri- toneal recurrence: postoperative and long-term results 显示文摘	Golse N Bakrin N Passot G	2012	J Surg Oncol2012，106，2：	1
	14	Quality of life after cytoreductive surgery plus hyperthermic intraperitoneal ehemo- therapy:a prospective study of 216 patients显示文摘	PASSOT G BAKRIN N ROUX A S	2014	Eur J Surg On- col2014，40，5：	1
	15	Cytoreductive surgery and HIPEC after neoadjuvant chemotherapy for advanced epithelial ovarian cancer显示文摘AIM: To reduce postoperative complications and to make possible an optimal cytoreduction, neoadjuvant chemotherapy(NACT) followed by interval debulking surgery has been applied with encouraging results. METHODS: Between December 2009 and February 2012, patients with stage ⅢC-Ⅳ epithelial ovarian cancer(EOC) underwent diagnostic laparoscopy, to assess the feasibility of optimal debulking surgery. The modifi ed Fagotti score was applied to assess the feasibility of resection with zero residual tumor. Patients who were not candidate for upfront debulking surgery were submitted to NACT, then reassessed according to the RECIST 1.1 criteria and submitted to cytoreductive surgery(CRS) and hyperthermic intraperitoneal chemotherapy(HIPEC) if they showed clinical response or stable disease. The remaining cycles of adjuvant systemic chemotherapy(ASCT) were administered postoperatively, to complete 6 cycles of systemic chemotherapy.RESULTS: Nine patients were included. Clinical response to NACT was complete in 3 patients and partial in 5 patients; one patient had stable disease. All patients underwent CRS resulting in CC0 disease prior to HIPEC. Average operative time was 510 min. Average intensive care unit stay was 2 d. Average postoperative hospital stay was 25 d. No postoperative mortality was observed. One patient experienced pelvic abscess. One patient refused ASCT. The remaining 8 patients started ASCT. Average time to chemotherapy was 36 d. All patients are alive, with an average follow up of 11 mo. Eight patients are disease-free at follow up.CONCLUSION: HIPEC after CRS for advanced EOC is feasible with acceptable morbidity and mortality. NACT may increase the chance for achieving complete cytoreduction. Phase 3 studies are needed to determine the effects of HIPEC on survival.	Marco Lotti Luisa Maria Busci Luca Campanati Fausto Catena Federico Coccolini Naoual Bakrin Pierandrea De Iaco Giorgio Ercolani Giuseppe Grosso Michele Pisano Elia Poiasina Diego Rossetti Martina Rossi Claudio Zamagni Paolo Bertoli Antonio Daniele Pinna Luigi Frigerio Luca Ansaloni	2013	World Journal of Obstetrics and Gynecology2013，2，4：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费